Updated Feb. 18, 2013 at 6:32 a.m.
GSK's R&D facility in RTP. (GSK photo)
Pharmaceutical stocks of GlaxoSmithKline among others, which have soared in the past year to valuations not seen since 2001, are poised to extend their rally as investors grow more confident the industry has weathered a decade-long shortage of new drugs.
For GSK, other drug giants, pipelines rebound - and so do stocks
Post a comment
Print this blog postE-mail blog post
Share
GSK's R&D facility in RTP. (GSK photo)
Pharmaceutical stocks of GlaxoSmithKline among others, which have soared in the past year to valuations not seen since 2001, are poised to extend their rally as investors grow more confident the industry has weathered a decade-long shortage of new drugs.
WRAL Tech Wire any time: Twitter, Facebook
Copyright 2013 WRAL Tech Wire. All rights reserved.Log in or upgrade to view WRALTechWire Insider content
To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.
Please Log In to add a comment.
Best of TechWire Insider
OUR INSIDERS
WRAL TechWire Editor
The Skinny
Durham's high-tech infrastructure, talent lure Virginia company- Lenovo acknowledges layoffs in Morrisville as part of shift to 'PC Plus' strategy
- Raleigh-based PRA International eyes public offering
- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows
- Titans of tech seek to excite UNC, Duke grads about a future beyond themselves
- Triangle politician tries to accelerate crowdfunding; bill passes first hurdle